Canada markets open in 7 hours 27 minutes
  • S&P/TSX

    18,457.78
    +76.82 (+0.42%)
     
  • S&P 500

    3,821.35
    -20.59 (-0.54%)
     
  • DOW

    31,802.44
    +306.14 (+0.97%)
     
  • CAD/USD

    0.7897
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    64.88
    -0.17 (-0.26%)
     
  • BTC-CAD

    68,155.36
    +3,482.04 (+5.38%)
     
  • CMC Crypto 200

    1,085.14
    +60.93 (+5.95%)
     
  • GOLD FUTURES

    1,690.50
    +12.50 (+0.74%)
     
  • RUSSELL 2000

    2,202.98
    +10.77 (+0.49%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,372.50
    +75.25 (+0.61%)
     
  • VOLATILITY

    25.47
    +0.81 (+3.28%)
     
  • FTSE

    6,719.13
    +88.61 (+1.34%)
     
  • NIKKEI 225

    29,027.94
    +284.69 (+0.99%)
     
  • CAD/EUR

    0.6662
    0.0000 (0.00%)
     

Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer

Constellation Pharmaceuticals , Inc.
·4 min read

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the Company’s commercial organization and pre-launch preparations in support of CPI-0610, which has the potential to be a disease-modifying therapy for patients living with myelofibrosis.

“Brendan is joining Constellation at a pivotal time, and I look forward to working with him to advance the treatment paradigm for patients with myelofibrosis,” said Jigar Raythatha, President and Chief Executive Officer of Constellation Pharmaceuticals. “With more than 25 years of experience in hematology and oncology commercialization, Brendan’s expertise will be invaluable as we prepare for the potential launch of our first product, CPI-0610—the first potential new myelofibrosis therapy beyond JAK inhibitors.”

“I am excited to join Constellation and look forward to leading preparations for the Company’s first commercial product launch,” said Brendan Delaney, Chief Commercial Officer of Constellation Pharmaceuticals. “It’s gratifying to work toward advancing the standard of care for patients with myelofibrosis. CPI-0610 is a highly promising Phase 3 product candidate with the potential to address unmet medical needs that have been identified by both patients and physicians.”

Mr. Delaney has a track record of global commercial success that spans more than two decades in the biopharmaceutical industry. Prior to joining Constellation, Mr. Delaney served as Chief Commercial Officer at Immunomedics, where he built and led the marketing, sales, market access, and commercial operations teams in preparation for that Company’s first commercial product launch. Previously, he served in several senior positions of increasing responsibility at Celgene, including most recently as Vice President, U.S. Commercial Hematology Oncology. Earlier in his career, Brendan held various sales, marketing and product management roles at Novartis Oncology and Genentech, where he directed successful product launches for several blockbuster brands. He earned an MBA from the Stern School of Business at New York University and a B.A. in biology from Rutgers University.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is advancing development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative, small-molecule product candidates.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the Company’s regulatory and commercial plans and prospects of the Company’s product candidate, CPI-0610. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to: obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials; obtain, maintain, or protect intellectual property rights related to its product candidates; manage expenses; raise the substantial additional capital needed to achieve its business objectives; the COVID-19 pandemic; and general economic and market conditions. For a discussion of other risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission.

Contacts

Kia Khaleghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com